We provide a unique, scientific environment for today’s complex drug development and testing.
We understand the need to maximize success while minimizing time and costs. That’s why we strategically positioned our laboratories within close proximity to our clinical research units and developed our Fast Track approach—an efficient and powerful process that can save you six to 12 months on your entire Phase I-IIa development program. We’ve achieved a 95% on-time study start and completion rate through our innovative application of technology, integration of clinical and bioanalytical services, and unique access to patients.
Where you need us. When you need us.
We operate state-of-the-art facilities in the Netherlands and North America, as well as an innovative patient pharmacology model in Central and Eastern Europe. Our harmonized laboratory facilities are situated close to clinical facilities and are configured with the latest technologies, diagnostic tools, and infrastructure required to fully support all clinical study requirements across a wide range of drugs and indications.
We also have extensive experience managing global Phase I clinical sites with healthy volunteers, including in Asia Pacific, and we routinely manage third-party clinical sites through our external site management model.
State-of-the-art Clinical Facilities
We provide end-to-end bioanalytical support from Pre-clinical to Phase IV studies. At PRA, our laboratories are managed, staffed, and supported by…
Fully supporting early phase projects from start to finish.
From protocol design to Clinical Study Report (CSR) delivery, we can meet the needs of essentially any early phase study for healthy volunteers, special populations, and early patient trials, including:
- Supporting the manufacturing and Qualified Person (QP) release of any formulation of a drug.
- Providing real-time support for pharmacokinetics (PK) and biomarker analysis.
- Facilitating shortened timelines in early development.
- Converting raw data into decision-point data for our clients.
Our early development solutions include drug development programs, exploratory clinical trials, fast track development, pain studies, patient pharmacology, and target product profiles.View Early Phase Patient Studies
Effectively executing trials in healthy volunteers and patient populations.
We conduct clinical trials in both healthy volunteers and patient populations, accommodating our in-house Phase I volunteers at our state-of-the-art Clinical Pharmacology Centers, where they are under constant medical supervision. Offering a full suite of Phase I-IIa clinical research services and a globally harmonized service, these centers also provide a large pool of more than 40,000 healthy volunteers, special equipment to monitor safety and pharmacodynamics, an in-house pharmacy, and expedited regulatory approval.
Our eight clinical pharmacology centers have the capabilities and experience to quickly randomize patients, and four of our centers are 100% dedicated to early phase patient studies, both in Europe and the US. In Central and Eastern Europe, we perform early patient trials in collaboration with our extensive network of investigators throughout the region. Our US centers specialize in the conduct and design of early-stage, patient population studies, and are therapeutically focused in Human Abuse Liability (HAL), addiction, pain, psychiatry, neurology, pediatric, and infectious disease services.View Phase I Healthy Volunteer Solutions
Bioanalysis, Biomarker and Flow Cytometry Assay List
Bioanalysis, Biomarker and Flow Cytometry Assay List. PRA Laboratories—Solutions for Drug Development. Behind every sample waiting to be analyzed,…
PRA Lenexa Lab Celebrates Ten-Year Anniversary
Clinical trial development is experiencing a surge in scientific breakthroughs, thanks to the introduction of new technologies and services. As we…
QC Laboratory as part of CMC Services at PRA’s Laboratories for Drug Development
The quality control laboratory facilitates the acceleration of drug development, supporting Clinical Phase I and II studies. From method…